tHEORetically Speaking

HealthEconomics.com
  • 0.0 (0)
  • BIOWISSENSCHAFTEN
  • HALBWÖCHENTLICH

Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/

  1. Weekly News Roundup — Oncology Shakeups, FDA Wellness Crackdown, and AI-Powered Drug Discovery

    12. DEZ. · BONUS

    Weekly News Roundup — Oncology Shakeups, FDA Wellness Crackdown, and AI-Powered Drug Discovery

    This week’s tHEORetically Speaking News Roundup covers GSK’s abrupt exit from its five-year synthetic lethality partnership with Ideaya, Whoop’s escalating regulatory clash with the FDA over its unapproved blood-pressure feature, and new evidence showing how minimum wage and EITC policies improve maternal mental health. We also break down Medra’s $52M raise and its new AI-driven drug-discovery partnership with Genentech.  Tune in for this concise recap of these pivotal industry updates!

    3 Min.
  2. Weekly News Roundup — Tariff-Free Pharma, Biologics Modernization, Duchenne Trial Success, and Maternal Health Advances

    5. DEZ. · BONUS

    Weekly News Roundup — Tariff-Free Pharma, Biologics Modernization, Duchenne Trial Success, and Maternal Health Advances

    This week’s tHEORetically Speaking News Roundup breaks down four major developments shaping policy and biopharma. We cover the new US–UK trade deal exempting pharma from tariffs and resetting NHS pricing, the FDA’s push to curb non-human primate testing for monoclonal antibodies, and Capricor’s breakthrough Phase 3 results in Duchenne muscular dystrophy. We also highlight new HEOR research using copula modeling to better understand drivers of low birth weight and preterm birth.  Tune in for a fast, 4-minute briefing on the most important shifts across science, regulation, and market access.

    4 Min.
  3. Weekly News Roundup — Premium Hikes, Predictive AI Breakthroughs, and Public Health Policy Fallout

    21. NOV. · BONUS

    Weekly News Roundup — Premium Hikes, Predictive AI Breakthroughs, and Public Health Policy Fallout

    This week’s tHEORetically Speaking News Roundup covers Medicare’s 10% Part B premium hike for 2026 and its potential to push more seniors toward Medicare Advantage, Clairity’s $43M raise to expand its FDA-cleared predictive AI platform beyond mammography, and the RISE Committee’s controversial move to exclude public health degrees from its professional program definition. Tune in for this concise recap of these pivotal policy, innovation, and workforce updates!

    4 Min.
  4. Weekly News Roundup — Four Big Moves in Medtech, Neurotech, Biopharma R&D & Pharma M&A

    14. NOV. · BONUS

    Weekly News Roundup — Four Big Moves in Medtech, Neurotech, Biopharma R&D & Pharma M&A

    This week on tHEORetically Speaking, we’re covering four major stories shaping the landscape across medtech, neurotech, drug development, and global pharma: Laborie buys Organon’s Jada system, NextSense raises a new round to launch EEG Smartbuds, Evotec and BMS hit an IND milestone, and Merck goes big with a $9.2B antiviral acquisition.  A fast, focused roundup of the headlines you need to know. Subscribe for weekly drops!

    3 Min.
  5. Weekly News Roundup – FDA Shakeups, Novo Nordisk’s Strategic Reset, and Smart Data for Diabetes Innovation

    7. NOV. · BONUS

    Weekly News Roundup – FDA Shakeups, Novo Nordisk’s Strategic Reset, and Smart Data for Diabetes Innovation

    This week’s tHEORetically Speaking News Roundup covers the sudden resignation of the FDA’s top drug chief amid controversy, Novo Nordisk’s sweeping restructuring and strategic reset in the obesity and diabetes markets, and a groundbreaking data partnership between ŌURA and Tidepool driving innovation in diabetes research. We also explore how rising healthcare costs threaten the future of clinical trial diversity.  Tune in for this concise recap of these pivotal industry updates!

    4 Min.
  6. Weekly News Roundup – Neuro Breakthroughs, Biosimilar Reform, and an Obesity Drug Showdown

    31. OKT. · BONUS

    Weekly News Roundup – Neuro Breakthroughs, Biosimilar Reform, and an Obesity Drug Showdown

    This week’s tHEORetically Speaking News Roundup covers Evotec and Bristol Myers Squibb’s progress in developing next-generation therapies for neurodegenerative diseases, the FDA’s game-changing move to streamline biosimilar approvals and lower drug costs, and Novo Nordisk’s bold $6.5B counteroffer to outbid Pfizer for Metsera in the obesity treatment race. Tune in for this concise recap of the top stories shaping HEOR, RWE, and Market Access this week.

    4 Min.
  7. Weekly News Roundup – Real-World Wins and Billion-Dollar Breakthroughs

    24. OKT. · BONUS

    Weekly News Roundup – Real-World Wins and Billion-Dollar Breakthroughs

    This week’s tHEORetically Speaking News Roundup covers Astellas Pharma’s Phase 4 findings showing fezolinetant’s real-world benefits for menopausal symptom relief, improved sleep, and daily functioning. We also dive into Takeda’s $11 billion collaboration with Innovent Biologics to advance next-generation cancer therapies and expand its global oncology pipeline. Tune in for this concise recap of these pivotal industry updates!

    4 Min.
  8. INsights & OUTcomes with Dalfoni Banerjee

    21. OKT.

    INsights & OUTcomes with Dalfoni Banerjee

    This episode features Dalfoni Banerjee, an award-winning entrepreneur and consultant with over 30 years of hands-on experience and her expertise spans the full drug development cycle.  In 2011, Dalfoni founded and continues to operate 3Sixty Pharma Solutions, which has a mission to support startup and established pharmaceutical, biotechnology, and medical device companies with subject matter experts who help teams accelerate development, overcome challenges, and avoid preventable delays. Learn more about 3Sixty Pharma Solutions here: https://3sixtypharma.com/ Health Economics is moving fast. From value frameworks to AI driven modeling, you don't want to miss what's next. Join thousands of professionals who trust Health Economics.com as their go to resource. Subscribe for weekly insights, expert commentary, and the latest developments across HEOR and market access: https://healtheconomics.com/subscribe/

    19 Min.
Alle anzeigen (69)

Info

Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/

Informationen

  • Erstellt von
    HealthEconomics.com
  • Jahre aktiv
    2025
  • Folgen
    69
  • Bewertung
    Anstößig
  • Copyright
    © 2025 tHEORetically Speaking
  • Sendungswebsite
    tHEORetically Speaking